TET2 is involved in the self-renewal of HSCs, lineage commitment, and terminal differentiation of hematopoietic cells into specific lineages [12]. TET2 nucleotide variants abrogating TET2 enzymatic activity, and hence a reduction in the 5-hmC levels in the bone marrow, are associated with various hematological neoplasms including AML [13, 14]. Here, TET2 is linked to hematopoietic and lymphoid system neoplasm.